Cover Image
市場調查報告書

呼吸疾病治療藥的全球市場

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way

出版商 GBI Research 商品編碼 369232
出版日期 內容資訊 英文 202 Pages
訂單完成後即時交付
價格
Back to Top
呼吸疾病治療藥的全球市場 Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way
出版日期: 2016年08月01日 內容資訊: 英文 202 Pages
簡介

到目前的呼吸疾病治療方法,大部分都非解除病因,而是緩和疾病的症狀的小分子療法。可是,這10年來治療方法大幅進化,開發出許多新治療藥和標靶治療。2015年11月時,全部有908種產品,作為呼吸疾病治療藥進行臨床實驗。

本報告提供全球呼吸疾病治療藥的市場現況與未來展望相關分析,主要的呼吸疾病概要,及現在已上市的產品的概要,現在臨床實驗中的開發中產品一覽和臨床實驗的進展,今後的市場成長、技術開發 (臨床實驗進展)的預測,主要企業的概要與競爭策略,今後的產業重組預測等相關調查與考察。

第1章 目錄

第2章 簡介

  • 醫療領域:概論
  • 流行病學
    • 氣喘
    • 慢性閉塞性肺纖維化 (COPD)
    • 突發性肺纖維化 (IPF)
    • 囊狀纖維化症 (CF)
  • 病理生理學
  • 症狀
  • 診斷方法
  • 疾病的嚴重度和預後
  • 治療方法

第3章 主要已上市產品

  • 概要
  • Advair - GSK
  • Spiriva - Boehringer Ingelheim, Pfizer
  • Symbicort - AstraZeneca/Astellas
  • Singulair (montelukast) - Merck & Co.
  • Flixotide/Flovent - GSK
  • Ventolin - GSK
  • Kalydeco - Vertex
  • Pulmozyme - Roche
  • Esbriet - Roche
  • TOBI - Novartis
  • 結論

第4章 開發中產品的市場環境分析

  • 概要
  • 開發中產品的開發環境
  • 開發平台上的分子標的
  • 臨床實驗的進展
    • 失敗率:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 臨床實驗的有效期:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 臨床實驗的規模:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 整體臨床實驗計劃數:臨床實驗的各階段、各適應症、各分子類型,各分子標的
    • 結論

第5章 多方案市場分析 (到2022年)

  • 市場規模:概要
  • 學名藥的普及率
  • 各分子標的收益額預測
    • G蛋白偶聯受體
    • 免疫/發炎媒介物質
    • 轉錄因子
    • 信號傳達
    • CFTR (囊狀纖維化症薄膜傳導控制因素) 調整劑
  • 主要的開發中產品的評估
    • Dupilumab - Regeneron Pharmaceuticals/Sanofi
    • Benralizumab - AstraZeneca/Medimmune
    • Lebrikizumab - Roche/Genentech
    • PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics
    • Tralokinumab - AstraZeneca
    • Batefenterol - GSK/Theravance
    • 結論

第6章 企業的分析與定位

  • 各企業的收益額、市場佔有率分析
    • GlaxoSmithKline
    • Vertex
    • AstraZeneca
    • Roche
    • Novartis
    • Boehringer Ingelheim
  • 企業環境
  • 已上市/開發中產品的組合分析

第7章 產業重組的策略

  • 授權合約交易
    • 各地區、各年度的交易趨勢/金額
    • 各臨床實驗階段的交易趨勢/金額
    • 各分子類型、各分子標的交易趨勢
    • 交易額1億美元以上的交易的一覽
  • 共同開發交易

第8章 附錄

  • 參考文獻
  • 全開發中產品:各階段 (相位)
  • 簡稱一覽
  • 分析方法
  • 聯絡處資訊
  • 免責聲明

圖表一覽

目錄
Product Code: GBIHC409MR

Respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function. The market size for respiratory therapeutics is expected to grow strongly, from USD28.1 Billion in 2015 to USD46.6 Billion in 2022, at a compound annual growth rate (CAGR) of 7.5%.

The patent expirations of the commercially successful Advair, Symbicort, Ventolin and Spiriva will allow generics to enter the market, but the impact of these expirations will be offset by the approval of new products. Recently approved products in chronic obstructive pulmonary disease (COPD) include multiple long-acting beta-2 agonist/long-acting muscarinic antagonist (LAMA) fixed-dose combinations, some of which are forecast to generate over USD1 Billion by 2022.

Respiratory pipeline consists of 908 pipeline products, most of which are small molecules and monoclonal Antibody (mAb) products. Most of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 64.3%. Phase I, II and III products account for 31.3%, and Pre-registration products account for a mere 2%.

In 2015, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 33.6% of the market, while Vertex had a small market share of only 2.8%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Kalydeco and Orkambi, both of which were developed by Vertex. They are forecast to generate USD2.8 Billion and USD6.8 Billion, respectively, by 2022, driven by strong demand for disease modifying therapy in CF. Vertex also has a Phase III candidate of the same class, which is forecast to contribute more than USD1 Billion by 2022.

The report “Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way” provides an introduction to respiratory disorders, including disease epidemiology, symptoms, pathophysiology, co-morbidities and complications and prognosis.

In particular, it provides the following analysis:

  • Provides an overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analysis of the respiratory disorders pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: asthma, chronic obstructive pulmonary disease, cystic fibrosis and idiopathic pulmonary fibrosis.
  • Provides forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company's pipeline portfolio and total revenues.
  • Analysis of trends in co-development and licensing deals, relating to respiratory disorder products. Some of the most prominent deals are discussed in detail.

Companies mentioned in this report: Vertex Pharmaceuticals, GlaxoSmithKline, AstraZeneca, Roche, Boehringer Ingelheim, Novartis, Teva Pharmaceutical, Merck & Co, Sanofi, Pfizer, Kyorin Holdings, Astellas Pharma, Insmed Incorporated, Mallinckrodt, Sumitomo Dainippon Pharma, Infinity Pharmaceuticals, Bayer, Regeneron Pharmaceuticals, Almirall, Shionogi & Co, Jazz Pharmaceuticals, Orion Oyj, Par Pharmaceutical, AbbVie, UCB, Takeda, Santen Pharmaceutical, Nippon Shinyaku, Daiichi Sankyo, Meiji Seika Pharma, Johnson & Johnson, Gilead Sciences, VIVUS, Teijin, Horizon Pharma, Cempra.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Epidemiology
    • 2.2.1. Asthma
    • 2.2.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.2.3. Idiopathic Pulmonary Fibrosis
    • 2.2.4. Cystic Fibrosis
  • 2.3. Pathophysiology
    • 2.3.1. Asthma
    • 2.3.2. Chronic Obstructive Pulmonary Disease
    • 2.3.3. Idiopathic Pulmonary Fibrosis
    • 2.3.4. Cystic Fibrosis
  • 2.4. Symptoms
  • 2.5. Diagnosis
    • 2.5.1. Asthma
    • 2.5.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.5.3. Idiopathic Pulmonary Fibrosis
    • 2.5.4. Cystic Fibrosis
  • 2.6. Disease Severity and Prognosis
    • 2.6.1. Asthma
    • 2.6.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.6.3. Idiopathic Pulmonary Fibrosis
    • 2.6.4. Cystic Fibrosis
  • 2.7. Treatment
    • 2.7.1. Asthma
    • 2.7.2. Chronic Obstructive Pulmonary Fibrosis
    • 2.7.3. Idiopathic Pulmonary Fibrosis
    • 2.7.4. Cystic Fibrosis

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Advair - GSK
  • 3.3. Spiriva - Boehringer Ingelheim, Pfizer
  • 3.4. Symbicort - AstraZeneca/Astellas
  • 3.5. Singulair (montelukast) - Merck & Co.
  • 3.6. Flixotide/Flovent - GSK
  • 3.7. Ventolin - GSK
  • 3.8. Kalydeco - Vertex
  • 3.9. Pulmozyme - Roche
  • 3.10. Esbriet - Roche
  • 3.11. TOBI - Novartis
  • 3.12. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion

5. Multi-scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. G-Protein Coupled Receptors
    • 5.3.2. Immune/Inflammatory Mediators
    • 5.3.3. Transcription Factors
    • 5.3.4. Signal Transduction
    • 5.3.5. CFTR Modulator
  • 5.4. Assessment of Key Pipeline Products
    • 5.4.1. Dupilumab - Regeneron Pharmaceuticals/Sanofi
    • 5.4.2. Benralizumab - AstraZeneca/Medimmune
    • 5.4.3. Lebrikizumab - Roche/Genentech
    • 5.4.4. PT010(Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics
    • 5.4.5. Tralokinumab - AstraZeneca
    • 5.4.6. Batefenterol - GSK/Theravance
    • 5.4.7. Conclusion

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. GlaxoSmithKline
    • 6.1.2. Vertex
    • 6.1.3. AstraZeneca
    • 6.1.4. Roche
    • 6.1.5. Novartis
    • 6.1.6. Boehringer Ingelheim
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deal by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type and Molecular Target
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. Bibliography
  • 8.2. All Pipeline Drugs by Phase
    • 8.2.1. Discovery
    • 8.2.2. Preclinical
    • 8.2.3. IND/CTA filed/Phase 0
    • 8.2.4. Phase I
    • 8.2.5. Phase II
    • 8.2.6. Phase III
    • 8.2.7. Pre-registration
  • 8.3. Abbreviations
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2016
  • Table 2: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
  • Table 3: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
  • Table 4: Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults
  • Table 5: Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016
  • Table 6: Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016
  • Table 7: Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016
  • Table 8: Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016
  • Table 9: Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016
  • Table 10: Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016
  • Table 11: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2016
  • Table 12: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Spiriva, 2016
  • Table 13: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2016
  • Table 14: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2016
  • Table 15: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Flixotide, 2016
  • Table 16: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2016
  • Table 17: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2016
  • Table 18: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmozyme, 2016
  • Table 19: Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2016
  • Table 20: Respiratory Disorders Therapeutics Market, Global, Approved Indications for TOBI, 2016
  • Table 21: Respiratory DIsorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016
  • Table 22: Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016
  • Table 23: Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Table 24: Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
  • Table 25: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2016
  • Table 26: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2016
  • Table 27: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA filed/Phase 0, 2016
  • Table 28: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2016
  • Table 29: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2016
  • Table 30: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2016
  • Table 31: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2016

List of Figures

  • Figure 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Asthma, 2015-2023
  • Figure 2: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for COPD, 2015-2023
  • Figure 3: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Idiopathic Pulmonary Fibrosis, 2015-2023
  • Figure 4: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Cystic Fibrosis, 2015-2023
  • Figure 5: Respiratory Disorders Therapeutics Market, Clinical Courses of IPF
  • Figure 6: Respiratory Disorders Therapeutics Market, Progression of CF
  • Figure 7: Respiratory Disorders Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2016
  • Figure 8: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Advair ($bn), 2006-2022
  • Figure 9: Respiratory Disorders Therapeutic Market, Global, Annual Revenues for Spiriva ($bn), 2006-2022
  • Figure 10: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Symbicort ($bn), 2006-2022
  • Figure 11: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Singulair ($bn), 2006-2022
  • Figure 12: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Flixotide ($m), 2006-2022
  • Figure 13: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Ventolin ($m), 2006-2022
  • Figure 14: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for Kalydeco ($bn), 2012-2022
  • Figure 15: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Pulmozyme ($m), 2006-2022
  • Figure 16: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Esbriet ($bn), 2011-2022
  • Figure 17: Respiratory Disorders Therapeutics Market, Global, Annual Revenues for TOBI ($m), 2006-2020
  • Figure 18: Respiratory Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 19: Respiratory Disorders Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 20: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Stage of Development, 2016
  • Figure 21: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecule Type, 2016
  • Figure 22: Respiratory Disorders Therapeutics Market, Global, Pipeline by Molecular Targets and Stage of Development, 2016
  • Figure 23: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecular Targets, 2016
  • Figure 24: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 25: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 26: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 27: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 28: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
  • Figure 29 Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 30: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 31: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 32: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development, 2006-2016
  • Figure 33: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006-2016
  • Figure 34: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006-2016
  • Figure 35: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006-2016
  • Figure 36: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development, 2006-2016
  • Figure 37: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication, 2006-2016
  • Figure 38: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006-2016
  • Figure 39: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2016
  • Figure 40: Respiratory Disorders Therapeutics Market, Global, Market Size ($bn), 2015-2022
  • Figure 41: Respiratory DIsorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Figure 42: Respiratory Disorders Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
  • Figure 43: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Modulators ($bn), 2015-2022
  • Figure 44: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Immune/Inflammatory System Targets ($bn), 2015-2022
  • Figure 45: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Transcription Factor Therapies ($bn), 2015-2022
  • Figure 46: Respiratory DIsorders Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction Modulators ($bn), 2015-2022
  • Figure 47: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for CFTR Modulators ($bn), 2015-2022
  • Figure 48: Respiratory Disorders Therapeutics Market, Global, Revenue for Dupilumab ($bn), 2017-2022
  • Figure 49: Respiratory DIsorders Therapeutics Market, Global, Revenue for Benralizumab ($m), 2018-2022
  • Figure 50: Respiratory Disorders Therapeutics Market, Global, Revenue for Lebrizikumab ($m), 2017-2022
  • Figure 51: Respiratory Disorders Therapeutics Market, Global, Revenue for PT010 ($m), 2017-2022
  • Figure 52: Respiratory Disorders Therapeutics Market, Global, Revenue for Tralokinumab ($m), 2017-2022
  • Figure 53: Respiratory Disorders Therapeutics Market, Global, Revenue for Batefenterol ($m), 2019-2022
  • Figure 54: Respiratory Disorders Therapeutics Market, Global, Cluster Graph by Growth and Market Share, 2015-2022
  • Figure 55: Respiratory Disorders Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 56: Respiratory Disorders Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
  • Figure 57: Respiratory Disorders Therapeutics Market, Global, Revenue by Product Type, 2015-2022
  • Figure 58: Respiratory Disorders Therapeutics Market, Global, GlaxoSmithKline Annual Revenue Forecast ($m), 2015-2022
  • Figure 59: Respiratory Disorders Therapeutics Market, Global, Vertex Annual Revenue Forecast ($m), 2015-2022
  • Figure 60: Respiratory DIsorders Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($m), 2015-2022
  • Figure 61: Respiratory Disorders Therapeutics Market, Global, Roche Annual Revenue Forecast ($m), 2015-2022
  • Figure 62: Respiratory Disorders Therapeutics Market, Global, Novartis Annual Revenue Forecast ($m), 2015-2022
  • Figure 63: Respiratory Disorders Therapeutics Market, Global, Boehringer Ingelheim Annual Revenue Forecast ($m), 2015-2022
  • Figure 64: Respiratory Disorders Therapeutics Market, Global, Companies by Type, 2016
  • Figure 65: Respiratory Disorders Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Respiratory Specialization, 2016
  • Figure 66: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, 2015-2022
  • Figure 67: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, Top Six Companies ($bn), 2015-2022
  • Figure 68: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2016
  • Figure 69: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Indication, 2006-2016
  • Figure 70: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Stage of Development, 2006-2016
  • Figure 71: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2016
  • Figure 72: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
  • Figure 73: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
  • Figure 74: Respiratory Disorders Therapeutics Market, Global, Co-development Deal Volume and Value by Stage of Development, 2006-2016
  • Figure 75: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2016
Back to Top